LBD
BMRN icon

Landsberg Bennett & Dubbaneh’s BioMarin Pharmaceuticals BMRN Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$408K Buy
+5,286
New +$417K 0.05% 186
2019
Q4 		– Sell
-2,963
Closed -$202K – 245
2019
Q3 		$202K Sell
2,963
-351
-11% -$27K 0.05% 205
2019
Q2 		$279K Buy
+3,314
New +$284K 0.07% 192

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's BMRN Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2021: 5,286 shares worth $408K. The stake represents 0.05% of the portfolio and ranks #186 among its holdings. This is a return to the name: Landsberg Bennett & Dubbaneh previously reported a position in BMRN as recently as Q3 2019.

Landsberg Bennett & Dubbaneh first reported a position in BMRN in Q2 2019 and has held it in 3 quarters since. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Landsberg Bennett & Dubbaneh held 5,286 shares of BioMarin Pharmaceuticals worth $408K as of Q3 2021.
  • BioMarin Pharmaceuticals was a new Landsberg Bennett & Dubbaneh position in Q3 2021.
  • BioMarin Pharmaceuticals made up 0.05% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #186 holding.
  • Landsberg Bennett & Dubbaneh first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • 512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.